Plasma malondialdehyde (MDA) levels in breast and lung cancer patients.
about
Cytochrome P450 1A2 (CYP1A2) activity, mammographic density, and oxidative stress: a cross-sectional studySerum paraoxonase and arylesterase activities in patients with lung cancer in a Turkish population.Breast cancer and urinary biomarkers of polycyclic aromatic hydrocarbon and oxidative stress in the Shanghai Women's Health StudyBreast fine-needle aspiration malondialdehyde deoxyguanosine adduct in breast cancer.Do alterations in mitochondrial DNA play a role in breast carcinogenesis?Oxidative stress in cancer-bearing dogs assessed by measuring serum malondialdehyde.Mutant p53 protein expression and antioxidant status deficiency in breast cancerThe effect of radiotherapy and chemotherapy on osmotic fragility of red blood cells and plasma levels of malondialdehyde in patients with breast cancer.Type 2 Diabetes and Breast Cancer: The Interplay between Impaired Glucose Metabolism and Oxidant StressSingle-Nucleotide Polymorphisms and Markers of Oxidative Stress in Healthy Women.Biomarkers in Exhaled Breath Condensate and Serum of Chronic Obstructive Pulmonary Disease and Non-Small-Cell Lung Cancer.Mammographic density. Potential mechanisms of breast cancer risk associated with mammographic density: hypotheses based on epidemiological evidence.Plasma protein carbonyls and breast cancer risk in sisters discordant for breast cancer from the New York site of the Breast Cancer Family RegistryBurden of disease attributable to the Hebei Spirit oil spill in Taean, KoreaDifferential oxidative stress response in young children and the elderly following exposure to PM(2.5)Oxidative stress, obesity, and breast cancer risk: results from the Shanghai Women's Health Study.Local and systemic oxidant/antioxidant status before and during lung cancer radiotherapy.Lipid mediators involved in the oxidative stress and antioxidant defence of human lung cancer cells.Telomere length, oxidative damage, antioxidants and breast cancer risk.Plasma florescent oxidation products and breast cancer risk: repeated measures in the Nurses' Health Study.Plasma fluorescent oxidation products and risk of estrogen receptor-negative breast cancer in the Nurses' Health Study and Nurses' Health Study IIDietary iron intake and breast cancer risk: modulation by an antioxidant supplementationThe interplay between autophagy and ROS in tumorigenesis.Malondialdehyde Epitopes as Targets of Immunity and the Implications for Atherosclerosis.Human breast adenocarcinoma cytotoxicity and modulation of 7,12-dimethylbenz[a]anthracene-induced mammary carcinoma in Balb/c mice by Acacia catechu (L.f.) Wild heartwood.Malondialdehyde in exhaled breath condensate and urine as a biomarker of air pollution induced oxidative stress.Serum prolidase activity, oxidative stress, and nitric oxide levels in patients with bladder cancer.Alteration in apoptosis and cell cycle by celecoxib and/or fish oil in 7,12-dimethyl benzene (α) anthracene-induced mammary carcinogenesis.Significant relationships between a simple marker of redox balance and lifestyle behaviours; Relevance to the Framingham risk score.Antioxidant enzymes and lipid peroxidation in different stages of breast cancer.Oxidant stress and B vitamins status in patients with non-small cell lung cancer.Sensitive and selective quantification of free and total malondialdehyde in plasma using UHPLC-HRMS.An investigation into the serum thioredoxin, superoxide dismutase, malondialdehyde, and advanced oxidation protein products in patients with breast cancer.Comparison of the concentration of trace metals (Ni, Zn, Co, Cu and Se), Fe, vitamins A, C and E, and lipid peroxidation in patients with prostate cancer.Increased levels of urinary biomarkers of lipid peroxidation products among workers occupationally exposed to diesel engine exhaust.Abundance of DNA adducts of 4-oxo-2-alkenals, lipid peroxidation-derived highly reactive genotoxins.Comparison of changes in erythrocyte and platelet fatty acid composition and protein oxidation in advanced non-small cell lung cancer.Interplay between membrane lipid peroxidation, transglutaminase activity, and cyclooxygenase 2 expression in the tissue adjoining to breast cancer.Association of CYBA gene (-930 A/G and 242 C/T) polymorphisms with oxidative stress in breast cancer: a case-control study
P2860
Q21195169-F25C24AA-E4BA-4DE1-A10A-676D022C5504Q33278805-F2742A02-135C-48C3-A1FC-D8A3E32B0ABFQ33718754-5D001107-9395-4FB3-B984-C724B0BB7B31Q33798380-F71FD5ED-4137-4B0B-BE85-6166B46164E0Q33985107-30F5FD13-2DFF-479F-B6A3-767D4C5FD4A1Q34714826-01FF31B7-2E30-4A35-BE74-C588D2019DF0Q35729171-399B6395-1F5B-4860-A5E6-76AC4FE1A6DCQ35768829-3F5F690E-B03E-42C0-8266-EB3F736A41B6Q35782187-30AF0EEC-D79F-4A08-B08A-FB8C8AE4F11CQ36043495-F7F737CB-B624-45C1-B497-81626341827DQ36112558-E209CD8E-BCFE-4283-8CA4-6AE9666A532CQ36643000-21A9509B-EDCB-4EF9-B718-984F96ACA525Q37153515-EBBD28FB-23D6-4E0B-94FC-2AA7F09877A4Q37190339-98E64AEA-B1FB-4AE6-991D-1AED382B3A26Q37198707-CC30AB2D-9970-41C3-891D-F8B0F4966B7FQ37198982-8A4BE2CD-F557-4C35-A15C-1D3CB7D3515CQ37214261-709E025B-4EC7-45A3-8B1C-9058DBE21AD9Q37223268-6B7994F2-8805-4F8E-9606-47921030E3B5Q37307273-34325508-E54E-4FDA-AB14-759C18B19D83Q37345248-935DE93B-1F37-458F-816C-7148599AC2DCQ37371389-956780A7-846D-4935-A8AB-7A0CB4AF99FEQ37694742-1D4EFD09-91E6-4794-B970-AD607A710551Q38062538-339570F9-E611-4BC3-9D51-879F56288D7BQ38846881-5A5D133C-5A0E-402B-A30A-518036E5CAC4Q39246600-FC77212E-5B57-405A-8E2B-4584FFB9C664Q40436064-8C15CCD2-44B6-4BE7-A823-14B5CE338CC6Q42548111-2B8B99D1-1957-4834-BF7E-C43D0CD76108Q43634441-980B1B79-07F3-43F1-97CD-3D0988912E89Q44658274-DD4F7E8A-07F4-4C26-B434-94EDC255F620Q44828125-965CB6C1-210A-49BD-9FC6-4F0D2F984769Q45077604-3FCD3AE1-4085-4DE8-9B38-C608BEF616CDQ46337966-4E71547F-94C2-400A-8979-85E69074780AQ46874754-0E1063D1-6B37-453C-A921-A68291F33A9FQ46942308-43C4FF11-C2FD-49AA-9D79-E41159EFBC08Q47435127-0A483D41-B0BF-4C65-A505-F4BD9D3FB606Q49838329-7BEFAF63-6A75-4436-85AC-C5E6C66C0F81Q50731641-854529A3-B127-459E-9CDA-F35762AF0044Q51174871-7AE534E8-0139-48ED-9954-6045D2384E57Q57484064-C635D1B6-11D4-4336-8E04-D15E6C181A8F
P2860
Plasma malondialdehyde (MDA) levels in breast and lung cancer patients.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
2001年论文
@zh
2001年论文
@zh-cn
name
Plasma malondialdehyde (MDA) levels in breast and lung cancer patients.
@en
type
label
Plasma malondialdehyde (MDA) levels in breast and lung cancer patients.
@en
prefLabel
Plasma malondialdehyde (MDA) levels in breast and lung cancer patients.
@en
P2093
P2860
P1476
Plasma malondialdehyde (MDA) levels in breast and lung cancer patients.
@en
P2093
P2860
P304
P356
10.1046/J.1365-2710.2001.00334.X
P577
2001-04-01T00:00:00Z